Monday 22 January 2018
Contact US    |    Archive
PR
4 months ago

Novartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data

EAST HANOVER, N.J., Sept. 13, 2017 /PRNewswire/ -- Novartis announced today first of its kind Phase

Read on the original site


هذه الصفحة هي مجرد قاریء تلقائي للأخبار باستخدام خدمة الـ RSS و بأن نشر هذه الأخبار هنا لاتعني تأییدها علی الإطلاق.

Asian stocks mostly higher

- Saudi News Agency
Hashtags:   

Novartis

 | 

Cosentyx®

 | 

sets

 | 

the

 | 

new

 | 

benchmark

 | 

psoriasis

 | 

with

 | 

robust

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Fresh air for sale

- Theguardian

Most Popular (a week)

Categories - Countries
All News
All Countries